ESMO ADVANCED COURSE PROGRAMME
OPTIMISING LONG-TERM OUTCOMES IN ADVANCED/METASTATIC EGFR-MUTATED NSCLC

Singapore
18-19 January 2027

CO-CHAIRS Lizza Hendriks, Netherlands
Caicun Zhou, China

SPEAKERS Herbert Loong, Hong Kong SAR, China
Jessica Menis, Italy
Solange Peters, Switzerland
Luisella Righi, Italy
Stephanie P.L. Saw, Singapore
Yang Xia, China
Fei Zhou, China

LEARNING OBJECTIVES

- To identify optimal treatment strategies and clinical decision-making frameworks to improve long-term survival
- To characterise patterns of resistance and its management, including management of oligometastases and central nervous system (CNS)/leptomeningeal disease
- To develop optimal treatment of uncommon EGFR-mutated NSCLC

ACCREDITATION

The programme of this event has been accredited with **10 ESMO-MORA category 1 points.**
Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update his/her knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details please refer to esmo.org.

ACKNOWLEDGEMENTS

This educational programme has been supported by

Johnson&Johnson

ORGANISATION AND CONTACTS

ESMO Head Office
Education Department
Via Ginevra 4, 6900 Lugano, Switzerland
Email: courses@esmo.org
www.esmo.org

Monday, 18 January 2027

09:00-09:10	**Welcome and introduction**
10'	Welcome and learning objectives introduction Lizza Hendriks, NL and Caicun Zhou, CN
09:10-10:45	**Session 1 – Initial diagnosis and workup** Chair: Caicun Zhou, CN
20'	Diagnosis and pitfalls of molecular testing Luisella Righi, IT
20'	Classical EGFR-mutations: How to select a front-line treatment Stephanie P.L. Saw, SG
20'	Integration of local ablative therapy with systemic therapy Lizza Hendriks, NL
20'	Second-line treatment and beyond Fei Zhou, CN
15'	Q&A
10:45-11:15	*Coffee Break*
11:15-12:30	**Session 2 – Treatment of uncommon EGFR mutations and exon 20 insertions** Chair: Lizza Hendriks, NL
20'	Optimal treatment of uncommon EGFR mutations across treatment lines Caicun Zhou, CN
20'	First-line treatment EGFR exon 20 insertions Fei Zhou, CN
20'	Second-line and beyond for exon 20 insertions Herbert Loong, HK SAR, CN
15'	Q&A
12:30-13:30	*Lunch*
13:30-14:45	**Session 3 – Special situations and toxicities management** Chair: Caicun Zhou, CN
20'	CNS metastases Lizza Hendriks, NL
20'	Toxicity management in combinations regimens Stephanie P.L. Saw, SG
20'	Treatment of elderly and frail patients Jessica Menis, IT
15'	Q&A
14:45-15:15	*Coffee break*

15:15-16:50 **Session 4 – Future directions**
Chair: Lizza Hendriks, NL

20' Understanding and overcoming resistance to EGFR TKI: Mechanisms and dynamics
Caicun Zhou, CN

20' Use of liquid biopsy in addressing resistance
Luisella Righi, IT

20' Optimising the use of immunotherapy in EGFR-mutated NSCLC
Solange Peters, CH

20' Addressing drug-tolerant persister cells
Yang Xia, CN

15' Q&A

16:50-17:20 **Session 5 – Moving to non-metastatic**
Chair: Caicun Zhou, CN

20' How to manage stage III EGFR M+ lung cancer
Jessica Menis, IT

10' Q&A

19:00 *Networking dinner*

Tuesday, 19 January 2027

09:00-12:30 **Workshop sessions**

Three parallel workshop sessions with 20 delegates in each group (delegates will attend all 3 sessions on a rotational basis)

15' Introduction based on clinical cases presented by speakers
40' Discussion
5' Break

Workshop 1 **Oligomestasis, oligoprogression and systemic progression: How to best address**
60' Lizza Hendriks, NL
Jessica Menis, IT

Workshop 2 **Selecting the best first-line treatment for classical EGFR-mutated NSCLC**
60' Stephanie P.L. Saw, SG
Fei Zhou, CN

Workshop 3 **Exon 20 insertion**
60' Herbert Loong, HK SAR, CN
Caicun Zhou, CN

11:00-11:30 *Coffee break*

11:30-12:30 **Workshop continuation**

12:30-12:45 **Feedback on the workshops from each group**

12:45-12:55 **Synthesis and wrap-up**
Lizza Hendriks, NL and Caicun Zhou, CN

12:55-13:55 *Lunch*